Deletion of a Single Lysine Residue at Position 292 of CAMK2A Disrupts Protein Function, Causing Severe Epileptic Encephalopathy and Intellectual Disability

Genes (Basel). 2023 Jun 27;14(7):1353. doi: 10.3390/genes14071353.

Abstract

Background: The use of NGS technology has rapidly increased during the last decade, and many new monogenic neurodevelopmental disorders have emerged. Pathogenic variants in the neuronal CAMK2A gene have been recently associated with "intellectual developmental disorder, autosomal dominant 53″ (OMIM#617798), a syndrome characterized by variable clinical manifestations including mild to severe intellectual disability, delayed psychomotor development, delayed or absent speech, delayed walking, seizures, dysmorphic features and behavioral psychiatric manifestations as autism spectrum disorders, aggressive behavior, and hyperactivity. CAMK2A (OMIM*114078) encodes for a subunit of the calcium/calmodulin-dependent serine/threonine kinase II (CaMKII), which is predominately expressed in the brain, where it plays critical roles in synaptic plasticity, learning, and memory as well as in neuronal migration.

Methods and results: We hereby describe a thirty-five-year-old woman affected by severe intellectual disability with epileptic encephalopathy. We performed exome sequencing and found a de novo heterozygous variant in the CAMK2A gene (NM_171825.2: c.874_876delCTT; p.Lys292del), which was fully correlated with her phenotype. This is the first report of an inframe single amino acid deletion in a patient affected by intellectual developmental disorder autosomal dominant 53. The variant is predicted to affect protein structure and function and interaction with other proteins and hits a crucial functional site.

Discussion: We discuss our variant in relation to previously reported variants and with the objective of delineating possible genotype-phenotype correlations.

Keywords: CAMK2A gene; epileptic encephalopathy; exome sequencing; intellectual disability; neurodevelopmental disorders.

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Brain Diseases*
  • Calcium-Calmodulin-Dependent Protein Kinase Type 2 / genetics
  • Female
  • Humans
  • Intellectual Disability* / genetics
  • Intellectual Disability* / pathology
  • Lysine
  • Neurodevelopmental Disorders* / genetics
  • Protein Serine-Threonine Kinases

Substances

  • Lysine
  • Protein Serine-Threonine Kinases
  • CAMK2A protein, human
  • Calcium-Calmodulin-Dependent Protein Kinase Type 2

Grants and funding

C.L. and A.A. are supported by ANIA Foundation, ERG number 21.31. C.T.’s salary was supported by “PNRR-MAD-2022-12376472—BABY@NET: A technology-based National Surveillance Network for the early identification of Autism Spectrum Disorder and other Neurodevelopmental Disorders in at-risk populations”, funded by the European Union—Next Generation EU—NRRP M6C2—Investment 2.1 Enhancement and strengthening of biomedical research in the NHS.